Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease

PHASE3RecruitingINTERVENTIONAL
Enrollment

330

Participants

Timeline

Start Date

June 27, 2024

Primary Completion Date

December 31, 2028

Study Completion Date

June 30, 2029

Conditions
Systemic Lupus Erythematosus
Interventions
DRUG

Hydroxychloroquine

Hydroxychloroquine 200mg capsules. Administered orally.

DRUG

Placebo

Hydroxychloroquine-matching placebo capsule. Administered orally.

Trial Locations (10)

10010

RECRUITING

VA NY Harbor Healthcare System, New York

10016

RECRUITING

NYC Health + Hospitals/Bellevue, New York

RECRUITING

NYU Langone Health, New York

10021

RECRUITING

Hospital for Special Surgery, New York

10032

RECRUITING

Columbia University Irving Medical Center/New York Presbyterian, New York

10461

RECRUITING

Montefiore Medical Center/Albert Einstein College of Medicine, The Bronx

17033

RECRUITING

Penn State MS Hershey Medical Center, Hershey

73104

RECRUITING

Oklahoma Medical Research Foundation, Oklahoma City

90095

RECRUITING

University of California, Los Angeles, Los Angeles

07601

RECRUITING

Hackensack Meridian Health, Hackensack

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

lead

NYU Langone Health

OTHER